2017/01/01 by Wael M Abdel-Rahman, Wael M. Abdel‐Rahman, Noura Alkhayyal +6
Immunology and Microbiology · Medicine · #Phagocytosis and Immune Regulation #Liver physiology and pathology #Cancer, Stress, Anesthesia, and Immune Response
paper · pdf · doi:10.3748/wjg.v23.i19.3440
AIM: gene, p53 protein) and its role in tumor invasion and response to therapy. METHODS: lines (all from colon cancers) as well as breast cancer cell lines MCF7 and 1001 (MCF7-p53 mutant clone). HeLa cell line was used as a positive control for epithelial to mesenchymal transition (EMT). AXL expression was determined by Western blotting using rabbit monoclonal antibody clone C89E7. AXL siRNA silencing was performed and followed by collagen invasion assay. Cell viability analysis using the sulforhodamine B assay and the invasion assay were performed after exposure to chemotherapeutic agents (doxorubicin for breast cancer cells; 5FU or irinotecan for colon cancer cells). RESULTS: wild-type cells. AXL silencing showed a subtle trend to restore colon cancer cell sensitivity to 5FU or irinotecan. Importantly, AXL expressing cells developed more invasive potential after exposure to chemotherapy compared to the AXL-silenced cells. CONCLUSION: AXL is influenced by p53 status and could cause the emergence of aggressive clones after exposure to chemotherapy. These findings could have applications in cancer management.